Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Captor Therapeutics S A currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners, meaning each pending case is under the review of a different official. The workload is also split across 2 distinct art units. This indicates that the company's current biotechnology applications are being examined in 2 different specialized groups within the patent office, rather than being concentrated under 1 technical authority.
The busiest examiner for the portfolio is MOORE, SUSANNA, who is responsible for 1 pending office action. This accounts for 1 of the 2 total pending actions for the company. Since each of the 2 distinct examiners is handling 1 pending action, the prosecution effort is divided. Practitioners must address the specific requirements of 2 different examiners across 2 separate art units. This distribution suggests that the pending Biotechnology & Pharmaceuticals matters involve distinct technical sub-fields that require different examiner expertise.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 1 | 68.1% | +31.6% |
| TRAN, SUSAN T | 1 | 62.8% | +35.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565630 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | MOORE, SUSANNA | — |
| 18040383 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | TRAN, SUSAN T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565630 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | MOORE, SUSANNA | — |
| 18040383 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | TRAN, SUSAN T | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18565630 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | MOORE, SUSANNA | 1624 | §103§112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18040383 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | TRAN, SUSAN T | 1615 | §102§103§112 | Final Rejection | — | Pending | Feb 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial